Haemacure to get $5 million investment from Swiss Red Cross:
This article was originally published in Clinica
Executive Summary
Haemacure is negotiating the terms of a SwFr7 million ($4.7 million) investment from ZLB, the central laboratory of the Swiss Red Cross. The funds will be used to launch Hemaseal APR, the Montreal-based company's fibrin sealant, the first such product to receive FDA approval. The product is used to stop bleeding and seal wounds in surgical procedures involving cardiopulmonary bypass, colostomy closure and spleen injuries.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.